Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-782 pembrolizumab plus chemotherapy in first-line nonsquamous non-small cell lung cancer
2018-002598-22Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Primary endpoint: Objective response. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-002598-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002598-22.